996 related articles for article (PubMed ID: 33154106)
61. Isolation, characterization, and structure-based engineering of a neutralizing nanobody against SARS-CoV-2.
Li T; Zhou B; Li Y; Huang S; Luo Z; Zhou Y; Lai Y; Gautam A; Bourgeau S; Wang S; Bao J; Tan J; Lavillette D; Li D
Int J Biol Macromol; 2022 Jun; 209(Pt A):1379-1388. PubMed ID: 35460753
[TBL] [Abstract][Full Text] [Related]
62. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
63. A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants.
Yang Z; Wang Y; Jin Y; Zhu Y; Wu Y; Li C; Kong Y; Song W; Tian X; Zhan W; Huang A; Zhou S; Xia S; Tian X; Peng C; Chen C; Shi Y; Hu G; Du S; Wang Y; Xie Y; Jiang S; Lu L; Sun L; Song Y; Ying T
Signal Transduct Target Ther; 2021 Nov; 6(1):378. PubMed ID: 34732694
[TBL] [Abstract][Full Text] [Related]
64. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain.
Wheatley AK; Pymm P; Esterbauer R; Dietrich MH; Lee WS; Drew D; Kelly HG; Chan LJ; Mordant FL; Black KA; Adair A; Tan HX; Juno JA; Wragg KM; Amarasena T; Lopez E; Selva KJ; Haycroft ER; Cooney JP; Venugopal H; Tan LL; O Neill MT; Allison CC; Cromer D; Davenport MP; Bowen RA; Chung AW; Pellegrini M; Liddament MT; Glukhova A; Subbarao K; Kent SJ; Tham WH
Cell Rep; 2021 Oct; 37(2):109822. PubMed ID: 34610292
[TBL] [Abstract][Full Text] [Related]
65. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2.
Song W; Gui M; Wang X; Xiang Y
PLoS Pathog; 2018 Aug; 14(8):e1007236. PubMed ID: 30102747
[TBL] [Abstract][Full Text] [Related]
66. Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function.
Yang TJ; Yu PY; Chang YC; Liang KH; Tso HC; Ho MR; Chen WY; Lin HT; Wu HC; Hsu SD
Nat Struct Mol Biol; 2021 Sep; 28(9):731-739. PubMed ID: 34385690
[TBL] [Abstract][Full Text] [Related]
67. [SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies: a review].
Chen Y; Lin J; Zheng P; Cao M; Jin T
Sheng Wu Gong Cheng Xue Bao; 2022 Sep; 38(9):3173-3193. PubMed ID: 36151792
[TBL] [Abstract][Full Text] [Related]
68. Peptide Platform as a Powerful Tool in the Fight against COVID-19.
Murdocca M; Citro G; Romeo I; Lupia A; Miersch S; Amadio B; Bonomo A; Rossi A; Sidhu SS; Pandolfi PP; Alcaro S; Sangiuolo FC; Novelli G
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452531
[TBL] [Abstract][Full Text] [Related]
69. Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein.
Wrobel AG; Benton DJ; Hussain S; Harvey R; Martin SR; Roustan C; Rosenthal PB; Skehel JJ; Gamblin SJ
Nat Commun; 2020 Oct; 11(1):5337. PubMed ID: 33087721
[TBL] [Abstract][Full Text] [Related]
70. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
Du S; Cao Y; Zhu Q; Yu P; Qi F; Wang G; Du X; Bao L; Deng W; Zhu H; Liu J; Nie J; Zheng Y; Liang H; Liu R; Gong S; Xu H; Yisimayi A; Lv Q; Wang B; He R; Han Y; Zhao W; Bai Y; Qu Y; Gao X; Ji C; Wang Q; Gao N; Huang W; Wang Y; Xie XS; Su XD; Xiao J; Qin C
Cell; 2020 Nov; 183(4):1013-1023.e13. PubMed ID: 32970990
[TBL] [Abstract][Full Text] [Related]
71. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode.
Zhao D; Liu L; Liu X; Zhang J; Yin Y; Luan L; Jiang D; Yang X; Li L; Xiong H; Xing D; Zheng Q; Xia N; Tao Y; Li S; Huang H
J Nanobiotechnology; 2022 Sep; 20(1):411. PubMed ID: 36109732
[TBL] [Abstract][Full Text] [Related]
72. A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding.
Yang J; Lin S; Sun H; Chen Z; Yang F; Lin X; Guo L; Wang L; Wen A; Zhang X; Dai Y; He B; Cao Y; Dong H; Liu X; Chen B; Li J; Zhao Q; Lu G
Front Immunol; 2022; 13():820336. PubMed ID: 35663966
[TBL] [Abstract][Full Text] [Related]
73. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
[TBL] [Abstract][Full Text] [Related]
74. A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19.
Huo J; Mikolajek H; Le Bas A; Clark JJ; Sharma P; Kipar A; Dormon J; Norman C; Weckener M; Clare DK; Harrison PJ; Tree JA; Buttigieg KR; Salguero FJ; Watson R; Knott D; Carnell O; Ngabo D; Elmore MJ; Fotheringham S; Harding A; Moynié L; Ward PN; Dumoux M; Prince T; Hall Y; Hiscox JA; Owen A; James W; Carroll MW; Stewart JP; Naismith JH; Owens RJ
Nat Commun; 2021 Sep; 12(1):5469. PubMed ID: 34552091
[TBL] [Abstract][Full Text] [Related]
75. A human monoclonal antibody blocking SARS-CoV-2 infection.
Wang C; Li W; Drabek D; Okba NMA; van Haperen R; Osterhaus ADME; van Kuppeveld FJM; Haagmans BL; Grosveld F; Bosch BJ
Nat Commun; 2020 May; 11(1):2251. PubMed ID: 32366817
[TBL] [Abstract][Full Text] [Related]
76. Slaying SARS-CoV-2 One (Single-domain) Antibody at a Time.
Czajka TF; Vance DJ; Mantis NJ
Trends Microbiol; 2021 Mar; 29(3):195-203. PubMed ID: 33446406
[TBL] [Abstract][Full Text] [Related]
77. The atomic portrait of SARS-CoV-2 as captured by cryo-electron microscopy.
Fertig TE; Chitoiu L; Terinte-Balcan G; Peteu VE; Marta D; Gherghiceanu M
J Cell Mol Med; 2022 Jan; 26(1):25-34. PubMed ID: 34904376
[TBL] [Abstract][Full Text] [Related]
78. [Development of a Series of Neutralizing Nanobodies against SARS-CoV-2 Spike Protein].
Zhuchkov VA; Ivanov SV; Kravchenko JE; Chumakov SP
Mol Biol (Mosk); 2023; 57(3):505-516. PubMed ID: 37326055
[TBL] [Abstract][Full Text] [Related]
79. Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters.
Aksu M; Kumar P; Güttler T; Taxer W; Gregor K; Mußil B; Rymarenko O; Stegmann KM; Dickmanns A; Gerber S; Reineking W; Schulz C; Henneck T; Mohamed A; Pohlmann G; Ramazanoglu M; Mese K; Groß U; Ben-Yedidia T; Ovadia O; Fischer DW; Kamensky M; Reichman A; Baumgärtner W; von Köckritz-Blickwede M; Dobbelstein M; Görlich D
Antiviral Res; 2024 Jan; 221():105778. PubMed ID: 38065245
[TBL] [Abstract][Full Text] [Related]
80. Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies.
Stefan MA; Light YK; Schwedler JL; McIlroy PR; Courtney CM; Saada EA; Thatcher CE; Phillips AM; Bourguet FA; Mageeney CM; McCloy SA; Collette NM; Negrete OA; Schoeniger JS; Weilhammer DR; Harmon B
MAbs; 2021; 13(1):1958663. PubMed ID: 34348076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
